Related Experiment Video
Updated: Dec 29, 2025
05:35
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
Published on: January 19, 2024
1.2K
Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland
Frank Loughnane1, Gorden Muduma2, Richard F Pollock3
1Department of Anaesthesiology and Intensive Care Medicine, University College Cork, Cork, Ireland.
Advances in Therapy
|February 8, 2020
Summary
Iron isomaltoside 1000/ferric derisomaltose (IIM) offers greater patient throughput and net financial benefit for pre-operative iron deficiency anemia (IDA) clinics in Ireland compared to ferric carboxymaltose (FCM). This analysis informs optimal resource allocation for IV iron services.
Area of Science:
- Hematology
- Health Economics
- Clinical Pharmacy
Background:
- Intravenous (IV) iron is crucial for patients with iron deficiency anemia (IDA) who cannot tolerate oral iron or require rapid iron repletion, particularly pre-operatively.
- Different IV iron formulations possess varying dosing characteristics that influence administration speed and maximum dosage.
- The implementation of dedicated IV iron clinics is an emerging strategy to optimize patient care and resource utilization.
Purpose of the Study:
- To develop a resource impact model for establishing IV iron clinics in Ireland.
- To compare the resource impact and cost-effectiveness of different IV iron formulations for pre-operative IDA treatment.
- To provide data-driven insights for clinicians and service providers on implementing innovative pre-operative IV iron services.
Main Methods:
- A resource impact tool was created to model resource utilization and treatment costs for IDA.
- The model focused on two fast-administration, high-dose IV iron formulations available in Ireland: iron isomaltoside 1000/ferric derisomaltose (IIM) and ferric carboxymaltose (FCM).
- Clinic throughput, fixed overheads, variable costs, patient income (public and private), and IV iron savings were incorporated into the analysis.
Main Results:
- Using IIM, a new pre-operative service with 12 infusion slots weekly could treat 474 patients annually, yielding a net annual clinic balance of €42,736.
- Utilizing FCM, the same service could treat 353 patients annually, resulting in a net annual clinic balance of €36,327.
- The analysis indicated a difference of 121 patients treated and €6,408 in net balance in favor of IIM over FCM.
Conclusions:
- Iron isomaltoside 1000/ferric derisomaltose (IIM) maximizes clinic throughput compared to other IV iron formulations.
- This analysis supports clinicians in Ireland to optimize service provision and expenditure for pre-operative IDA.
- The findings highlight the potential impact of establishing IV iron clinics for pre-operative IDA patients.
